ISOPS 13, Ankara, Türkiye, 21 - 23 Haziran 2021, ss.18-20
Three-dimensional printing (3DP) technology is the manufacturing process of 3D products by
layer to layer from digital designs using a 3D printer. While it has already been widely used in
many industries, the 3DP technology is still very new in the pharmaceutical industry (1). The
use of 3DP technologies in the pharmaceutical field is promising in the treatment of diseases
where the dose varies from person to person or according to the severity of the disease. In
colon-specific diseases such as colon cancer or Crohn's disease, in whose treatment
antineoplastic agents and corticosteroids are generally used, individual dosing is required to
increase the efficiency of the treatment (2). Personalized treatment in oral solid dosage forms
produced by conventional methods is generally achieved by using a large number of low-dose
drugs or by dividing higher-dose drugs. However, splitting of the tablets may lead to variations
in the dose taken. Especially in modified-release tablets such as delayed-release, extended-
release, and targeted-release, the division of the tablets may affect the release kinetics of the
drugs or lead to burst release as disrupting the integrity of the coating. Thus, dose
customization in these tablets is only possible by 3DP methods enabling flexible-dose
manufacturing techniques (3). Fused deposition modeling (FDM) is recently the most
researched 3DP method for pharmaceutical applications due to lower cost, ease of use and
portability, and a wide range of applications.
Eudragit S100 is the most commonly used pH-dependent coating polymer for colon targeting
tablets (4). However, it is difficult to produce a formulation including Eudragit S100 by FDM-
3DP due to its degradation at the glass transition temperature (5). There is no study in the
literature in which Eudragit S100 is printed below its degradation temperature.
This study aims to develop an Eudragit S100 coating filament that can be printed below its
degradation temperature by FDM-3DP to be a model for colon-specific tablets.